DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



New Treatment for Alcohol and Nicotine Dependence

Information source: University of Virginia
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alcohol Dependence; Nicotine Dependence

Intervention: Topiramate with brief behavioral enhancement therapy (Drug); Placebo with brief behavioral enhancement therapy (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: University of Virginia

Official(s) and/or principal investigator(s):
Nassima Ait-Daoud Tiouririne, MD, Principal Investigator, Affiliation: University of Virginia
Robert M Anthenelli, MD, Principal Investigator, Affiliation: University of California, San Diego
Paul M Cinciripini, PHD, Principal Investigator, Affiliation: M.D. Anderson Cancer Center
Bankole A Johnson, MD, Principal Investigator, Affiliation: University of Virginia

Overall contact:
Eva Jenkins-Mendoza, Phone: 1-888-882-2345, Email: emj9c@virginia.edu

Summary

This research study aims to test whether topiramate (a drug that is being used for seizure) will help individuals who have problems with both alcohol and nicotine. The investigators believe that individuals taking topiramate will be more successful at abstaining from both alcohol and nicotine than individuals taking placebo.

Clinical Details

Official title: High and Low Dose Topiramate for the Treatment of Alcohol-Dependent Smokers

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: percent heavy drinking days, continuous abstinence rate for smoking

Secondary outcome:

Quality of life

Craving for alcohol and nicotine

Detailed description: We propose a novel pharmacological strategy for treating alcohol and nicotine dependence concomitantly. The reinforcing effects of both alcohol and nicotine are mediated through the cortico-mesolimbic dopamine (CMDA) system, and the concomitant use of both drugs enhances their pharmacological effects. We propose a better approach to control dopamine (DA) effects by contemporaneous indirect modulation of DA release and its functional expression. Both DA release from its cell bodies in the ventral tegmental area and the expression of its reinforcing effects through the cortico-mesolimbic system are modulated by GABA efferents under the tonic control of glutamate-mediated excitatory amino acid pathways. Thus, it is reasonable to hypothesize that a medication that facilitates cortico-mesolimbic GABAergic function and inhibits glutamate action should diminish both nicotine's and alcohol's reinforcing effects by inhibiting the release of midbrain DA and its functional expression through pathways projecting from the nucleus accumbens to the cortex. The promise of this novel approach is exemplified by our recent proof-of-concept demonstration that topiramate compared with placebo significantly improved smoking abstinence rates and decreased serum cotinine levels among alcohol dependent smokers. An important clinical effect of topiramate in alcohol-dependent individuals appears to be that its anti-withdrawal effects promote the gradual tapering of drinking. Hence, due to this unique anti-withdrawal effect of topiramate, we propose to adopt the same methodology for treating alcohol-dependent individuals, as is common practice with smokers, of setting a target quit date (TQD) after which relapse to either drug can be measured. We propose an 18-week, double-blind clinical trial with follow-up visits at 1 month and 3 months, in which alcohol-dependent smokers will receive brief behavioral compliance enhancement treatment (BBCET) plus a smoking self-help manual as their psychosocial treatment, and will be randomized to receive placebo,high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day) to prevent relapse to heavy drinking and smoking. Each of the 3 treatment arms shall contain 98 individuals, with a total N of 294. The TQD will occur at the beginning of the 6th week of treatment. Our primary objective is to determine whether both low- and high-dose topiramate will be more efficacious than placebo at reducing the percentage of heavy drinking days and increasing the continuous abstinence rate for smoking determined by a combination of self-report and CO monitoring after the TQD and in the last 4 weeks of treatment. We also will be able to determine whether a lower dose of topiramate is as efficacious as the higher dose and, therefore, is associated with a lower adverse profile. Our secondary objectives are to test whether topiramate will be more efficacious than placebo at improving quality of life and reducing craving after the TQD and in the last 4 weeks of treatment and whether this improvement will be sustained in the follow-up phase.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Males and females who have given written informed consent

- Subjects must be above the age of 18

- Good physical health

- DSM-IV diagnosis of mild to severe alcohol use disorder

- Smoking ≥ 5 cigarettes/day

- Currently drinking at least 8 standard drink units (SDUs) per week for women and at

least 15 SDUs per week in the 30 days prior to randomization

- Subjects must provide evidence of stable residence

- The pregnancy test for females of child-bearing potential at screen and prior to

randomization must be negative. Additionally, women of child-bearing potential must be using an acceptable form of contraception.

- Literate in English and able to read, understand, and complete the rating scales and

questionnaires accurately, follow instructions, and make use of the behavioral treatments

- Willing to participate in a treatment program for alcohol and nicotine dependence

Exclusion Criteria: Please contact site for additional information

Locations and Contacts

Eva Jenkins-Mendoza, Phone: 1-888-882-2345, Email: emj9c@virginia.edu

University of California, San Diego, La Jolla, California 92093, United States; Recruiting
Nicole M Bekman, Ph.D., Phone: 858-534-9456, Email: nbekman@ucsd.edu
Robert M Anthenelli, MD, Principal Investigator

University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States; Recruiting
O'Neak Henigan, Phone: 713-745-4472, Email: OCHenigan@manderson.org
Paul M Cinciripini, Ph.D., Principal Investigator

University of Virginia Center for Addiction Research & Education, Charlottesville, Virginia 22911, United States; Recruiting
Eva Jenkins-Mendoza, Phone: 888-882-2345, Email: emj9c@virginia.edu
Nassima Ait-Daoud Tiouririne, MD, Principal Investigator

University of Virginia Center for Addiction Research & Education, Richmond, Virginia 23294, United States; Active, not recruiting

Additional Information

(UVA CARE Website)

Starting date: September 2011
Last updated: June 3, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017